ArticleInvestigational new drugs2013

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.

Aung Naing et al.PubMed ↗Publisher ↗

No numbers read from the abstract.